A fact that seems to be lost with most investor reports is that Serepta's Eteplirsen was only ever intended to work with 13-14% of DMD sufferers whereas Summit's drug will work with 100%
Good luck everyone Best HM
(0)
(0)
Summit Therapeutics plc (SMMT) Stock Research Links
